



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** p239SpE3' *nef* Open

**Catalog Number:** 2476

**Lot Number:** 99053

**Release Category:** C

**Provided:** 1 vial ampicillin-resistant transformed STBL2 cells.

**Cloning Vector:** pBS-.

**Special Characteristics:** Derived from p239SpE3' (Catalog #830), which encodes the 3' half of the SIV<sub>mac</sub>239 genome and has a premature stop at *nef* codon 93. Site-specific mutagenesis was used to make a TAA→GAA substitution, resulting in a fully open and functional *nef* open reading frame. The *Sst*I fragment from nucleotides 11,692-12,301 in the 3' flanking cellular sequence has also been deleted.

[Plasmid Map](#)

**Recommended Storage:** -70°C.

**Contributor:** Dr. Ronald Desrosiers, Dr. Jim Gibbs, and Dean Regier.

**References:** Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of SIV<sub>mac</sub> mutants with deletions in "nonessential" genes. *AIDS Res Hum Retroviruses* **10**:607-616, 1994. Regier DA, Desrosiers RC. The complete nucleotide sequence of a pathogenic clone of human immunodeficiency virus. *AIDS Res Hum Retroviruses* **6**:1221-1231, 1990. Kestler HW III, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the *nef* gene for maintenance of high virus loads and for development of AIDS. *Cell* **65**:651-662, 1991.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: p239SpE3' *nef* Open from Dr. Ronald Desrosiers." Also include the references cited above in any publications.

**Available only for non-commercial use. Requests from commercial organizations should be directed to Harvard Medical School Office of Technology Development at the following email address: [hms\\_materialtransfer@harvard.edu](mailto:hms_materialtransfer@harvard.edu).**

**Last Updated:**

May 10, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.